Syk - spleen tyrosine kinase Gene

Also Known as Sykb

Species: Mus musculus

Gene Type: protein coding
Gene ID: 20963

About Syk

Chromosome 13: 52,737,209-52,802,828 forward strand.GRCm39:CM001006.3

This gene has 5 transcripts (splice variants), 202 orthologues, 32 paralogues and is associated with 77 phenotypes. Biased expression in spleen adult (RPKM 36.), mammary gland adult (RPKM 7.6) and 11 other tissues.

Summary

Enables several functions, including ATP binding activity; SH2 domain binding activity; and enzyme binding activity. Involved in several processes, including cell surface receptor signaling pathway; myeloid cell activation involved in immune response; and regulation of vesicle-mediated transport. Acts upstream of or within several processes, including positive regulation of leukocyte activation; positive regulation of macromolecule metabolic process; and protein phosphorylation. Located in early phagosome. Part of B cell receptor complex. Is expressed in liver. Human ortholog(s) of this gene implicated in primary immunodeficiency disease. Orthologous to human Syk (spleen associated tyrosine kinase). [provided by Alliance of Genome Resources, Apr 2022]

Syk Products (2)

mRNA Protein Name
NM_001198977.1 NP_001185906.1 tyrosine-protein kinase SYK
NM_011518.2 NP_035648.2 tyrosine-protein kinase SYK

Syk Protein Structure

SH2_N-SH2_Zap70_Syk_like

SH2_N-SH2_Zap70_Syk_like: cd09938 (11 - 114)

SH2_C-SH2_Syk_like

SH2_C-SH2_Syk_like: cd10401 (162 - 260)

PTKc_Syk

PTKc_Syk: cd05116 (369 - 624)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 500
  • 600
  • 629 a.a.
Protein Preferred Names Protein Names

tyrosine-protein kinase SYK

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-13038A Fostamatinib Inhibitor 99.70% Yes
HY-13038 Fostamatinib Disodium Inhibitor 98.94% Yes
HY-13038B Fostamatinib disodium hexahydrate Inhibitor 99.46% Yes

Clinical Phase

Bioactive Molecules (15)
Cat. No. Product Name Effect
Purity Phase
HY-15968 Entospletinib Inhibitor 99.49% Phase 3
HY-15999 Cerdulatinib Inhibitor 99.06% Phase 3
HY-15999A Cerdulatinib hydrochloride Inhibitor 98.96% Phase 3
HY-15322 PRT062607 Inhibitor 99.38% Phase 2
HY-15323 PRT062607 Hydrochloride Inhibitor 98.07% Phase 2
HY-103018 Gusacitinib Inhibitor 99.63% Phase 2
HY-109091 Lanraplenib Inhibitor 99.13% Phase 2
HY-109082 Cevidoplenib Inhibitor 99.58% Phase 2
HY-109091B Lanraplenib succinate Inhibitor 98.09% Phase 2
HY-112319 (R,S)-MK-8457 / Phase 2
HY-100867 Mivavotinib Inhibitor / Phase 2
HY-109091A Lanraplenib monosuccinate Inhibitor / Phase 2
HY-103018A Gusacitinib hydrochloride Inhibitor / Phase 2
HY-13518 Piceatannol Inhibitor 98.97% Phase 1
HY-112809 GSK2646264 Inhibitor 99.74% Phase 1
Bioactive MoleculesInhibitory Antibodies (2)
Cat. No. Product Name Effect
Purity Phase
HY-P991734 VHB937 Activator 99.9% Phase 2
HY-P991954 GT103 / Phase 2

Pre-clinical Phase

Bioactive Molecules (65)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-12067 R406 Inhibitor 97.91% Unkown
HY-14985 BAY 61-3606 dihydrochloride Inhibitor 99.45% Unkown
HY-11108 R406 free base Inhibitor 99.07% Unkown
HY-100867A Mivavotinib monohydrochloride Inhibitor 99.91% Unkown
HY-N0805 Alisol B 23-acetate Inhibitor 99.65% Unkown
HY-12974 PRT-060318 Inhibitor 99.59% Unkown
HY-145598 Sovleplenib Inhibitor 99.94% Unkown
HY-N7675 Flavanomarein Inhibitor 99.92% Unkown
HY-112390A Syk Inhibitor II Inhibitor 98.15% Unkown
HY-78263 MNS Inhibitor 99.55% Unkown
HY-76474A BAY 61-3606 hydrochloride Inhibitor 98.08% Unkown
HY-174369 TREM2 agonist-3 Activator 99.39% Unkown
HY-12736A GSK143 dihydrochloride Inhibitor 99.37% Unkown
HY-131341 Syk-IN-4 Inhibitor 98.0% Unkown
HY-16420 R112 Inhibitor 98.90% Unkown
HY-136198 SRX3207 Inhibitor 98.50% Unkown
HY-P6442 Chemerin15 Inhibitor 99.65% Unkown
HY-16902 RO9021 Inhibitor 98.88% Unkown
HY-112386 OXSI-2 Inhibitor 99.9% Unkown
HY-15324 PRT062607 acetate Inhibitor 99.83% Unkown
HY-15324 PRT062607 acetate Inhibitor 99.83% Unkown
HY-160142 UBX-382 Inhibitor 96.20% Unkown
HY-109082A Cevidoplenib dimesylate Inhibitor 98.96% Unkown
HY-182702 As48 Activator / Unkown
HY-18623 VI 16832 Ligand 99.09% Unkown
HY-178324 T2M-010 Activator / Unkown
HY-178129 MRL-SYKi Inhibitor 98.97% Unkown
HY-108489 ER-27319 maleate Inhibitor 99.4% Unkown
HY-156872 MTX-216 Inhibitor / Unkown
HY-10230S Midostaurin-d5 Inhibitor 98.0% Unkown
HY-12974A PRT-060318 dihydrochloride Inhibitor 98.98% Unkown
HY-112390 Syk Inhibitor II dihydrochloride Inhibitor / Unkown
HY-138961 ER-27319 Inhibitor 98.66% Unkown
HY-12657 Syk-IN-1 Inhibitor 99.18% Unkown
HY-76474 BAY 61-3606 Inhibitor 98.21% Unkown
HY-124146 BI1002494 Inhibitor / Unkown
HY-184063 Vexicitinib Inhibitor / Unkown
HY-124605 IQS-019 Inhibitor / Unkown
HY-125500 TOP1362 Inhibitor / Unkown
HY-112390B Syk Inhibitor II dihydrochloride dihydrate Inhibitor / Unkown
HY-15322A (rel)-PRT062607 Inhibitor / Unkown
HY-155513 Syk-IN-8 Inhibitor / Unkown
HY-P2505 Syk Kinase Peptide Substrate / Unkown
HY-162427 NMS-0963 Inhibitor / Unkown
HY-120214 TAS05567 Inhibitor / Unkown
HY-156196 BI 894416 Inhibitor / Unkown
HY-125585 Syk-IN-2 Inhibitor / Unkown
HY-P2504 Syk Kinase Peptide Substrate, Biotin labeled / Unkown
HY-181546 Ibt-DOX Control / Unkown
HY-12736 GSK143 Inhibitor / Unkown
HY-149895 Syk-IN-7 Inhibitor / Unkown
HY-112390C Syk Inhibitor II hydrochloride Inhibitor / Unkown
HY-112319A MK-8457 Inhibitor / Unkown
HY-145029 SYK/JAK-IN-1 Inhibitor / Unkown
HY-184306 SYK-IN-15 Inhibitor / Unkown
HY-103018S Gusacitinib-d4 / Unkown
HY-169630 DBMB Inhibitor / Unkown
HY-N7314 Asebogenin Inhibitor / Unkown
HY-183924 SYK-IN-14 Inhibitor / Unkown
HY-174284 Syk-IN-13 Inhibitor / Unkown
HY-120533 Syk-IN-11 Inhibitor / Unkown
HY-160930 TOP1288 Inhibitor / Unkown
HY-N3702 Dehydroabietinol Inhibitor 98.90% Unkown
HY-18911 Type-II-IN-1 Inhibitor / Unkown
HY-123625 R-348 choline Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Syk NCBI NCBI:6850